Federico Cappuzzo

15PUBLICATIONS

252CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|Jul 15, 2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jul 14, 2026

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

|May 18, 2026

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

|Apr 10, 2026

First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.

Jhanelle E Gray, Joel W Neal, Jyoti D Patel

|Dec 03, 2025

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Tianshi Lu, Habib Hamidi, Mark A Socinski

|Aug 20, 2025

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.

Andrea Botticelli, Chiara Cremolini, Simone Scagnoli

Pageof 3

Frequent Collaborators

6 joint publications

Biagio Ricciuti

5 joint publications

Alessandro Di Federico

Mark Magdi Awad

Joao Victor Alessi

Stefano Scalera

Lorenza Landi

Marcello Maugeri-Saccà

4 joint publications

Laura Cipriani

3 joint publications

Daniele Marinelli

3 joint publications

Mihaela Aldea

Frequent Collaborators

6 joint publications

Biagio Ricciuti

5 joint publications

Alessandro Di Federico

5 joint publications

Mark Magdi Awad

4 joint publications

Joao Victor Alessi